Skip to main content

BrainsWay Ltd. (BWAY) Stock Forecast

Data as of Aug 7, 2026

Healthcare · Current price $15.39 (-1.34%)

Consensus Target
$16.00
Upside
+4.0%
Analysts
3
Rating
Buy(2.00)

Price Target Range

Low $15.00Consensus $16.00High $17.00
▲ Current $15.39

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

BWAY vs Sector & Market

MetricBWAYHealthcare AvgLarge Cap Avg
Analyst Rating2.002.252.42
Analyst Count3818
Target Upside+4.0%+16316.2%+17.2%
P/E Ratio81.353.3335.26

Revenue Estimates

PeriodLowAvgHigh#
2027-03-31$19M$19M$20M1
2027-06-30$20M$20M$21M1
2027-09-30$21M$21M$22M1
2027-12-31$22M$22M$23M1
2028-03-31$24M$25M$25M1
2028-06-30$25M$26M$26M1
2028-09-30$27M$27M$28M1
2028-12-31$28M$28M$29M1

EPS Estimates

PeriodLowAvgHigh#
2027-03-31$0.05$0.06$0.061
2027-06-30$0.06$0.06$0.061
2027-09-30$0.07$0.07$0.071
2027-12-31$0.08$0.08$0.081
2028-03-31$0.06$0.07$0.071
2028-06-30$0.06$0.07$0.071
2028-09-30$0.07$0.07$0.081
2028-12-31$0.08$0.08$0.081

Frequently Asked Questions

What is the analyst consensus for BWAY?

The consensus among 3 analysts covering BrainsWay Ltd. (BWAY) is Buy with an average price target of $16.00.

What is the highest price target for BWAY?

The highest analyst price target for BWAY is $17.00.

What is the lowest price target for BWAY?

The lowest analyst price target for BWAY is $15.00.

How many analysts cover BWAY?

3 analysts have issued ratings for BrainsWay Ltd. in the past 12 months.

Is BWAY a buy or sell right now?

Based on 3 analyst ratings, BWAY has a consensus rating of Buy (2.00/5) with a +4.0% upside to the consensus target of $16.00.

What are the earnings estimates for BWAY?

Analysts estimate BWAY will report EPS of $0.06 for the period ending 2027-03-31, with revenue estimated at $19M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.